

James B. Jumper

Partner

Philadelphia West (Berwyn) Philadelphia

james.jumper@troutman.com

D 610.640.7815



Jay advises clients on their major deals, including mergers and acquisitions and capital-raising transactions. Drawing on diverse industry experience, he also provides guidance to corporate stakeholders on a range of key issues.

OVERVIEW

Jay leads transactions for public and private companies and equity funds in stock and asset acquisitions, dispositions, mergers, joint ventures, and strategic alliance arrangements. He also represents private equity funds, venture capitalists, and emerging companies in private placements, venture capital, and other capital-raising deals.

Jay advises corporate boards of directors and other senior stakeholders on day-to-day legal issues in areas such as governance, strategic matters, contract review, and other commercial issues. He is experienced in sectors such as life sciences, health care technology, pharmaceutical, insurance, energy, and food and beverage, among others.

He is a co-host of the [2023 Mid-Atlantic Capital Conference](#), presented by PACT.

REPRESENTATIVE MATTERS

- Represented a NYSE-traded, multinational insurance broker and risk advisor in stock and asset acquisitions and mergers of numerous privately held insurance agencies in the commercial property and casualty, employee benefits, estate planning, executive benefits, life insurance, personal lines, and retirement services sectors.
- Represented a NYSE-traded, multinational publicly traded insurance broker in the disposition of one of its transaction-based wholesale insurance brokerage and surplus lines businesses to a private equity fund.
- Represented a privately held reinsurance company in its sale to a strategic buyer.
- Represented a privately held property-casualty and professional liability insurance brokerage in the sale of its assets to a NYSE-listed bank holding company.
- Represented the strategic division of a NYSE-traded company in connection with a preferred stock financing of a behavioral science and audited AI technology company.
- Represented the corporate venture arm of an integrated health care network in numerous early-stage and growth equity financing rounds (health IT, medical devices, therapeutics, diagnostics, and delivery solutions).

- Represented the corporate investment arm of an integrated health system in numerous early-stage and growth equity financings in the health care space.
- Represented a U.S.-based venture capital fund in connection with its investment in a Swiss-based financial advisor.
- Represented the venture arm of a NYSE-traded company in connection with numerous equity and debt financings (biotechnology, specialty pharmaceutical, and medical device spaces).
- Represented numerous venture capital syndicates and private equity funds in their investments; industry verticals include biotechnology, health care, manufacturing, specialty pharmaceutical, and technology.
- Represented numerous biotechnology and specialty pharmaceutical companies in connection with initial, follow-on, and mezzanine venture capital and institutional equity financing transactions.
- Handled multiple-stage equity financings of drug development and numerous therapeutic companies.
- Represented a Dublin, Ireland-based private equity group in several U.S.-based financings.
- Represented a private equity fund in its sponsorship of a leveraged recapitalization of an engineering design firm and subsequent add-on acquisitions.
- Represented a private equity firm in its formation of a consolidator in the aviation industry and the subsequent acquisition of several fixed-base operators throughout the U.S. that was financed by venture capital and senior and mezzanine debt financings.
- Represented a private equity firm in its formation of a consolidator in the technology and marketing solutions sector and the subsequent acquisition of several companies throughout the U.S.
- Represented a Nasdaq-traded alternative investment management firm in the sale of its portfolio company in the fund administration, accounting, tax, and management portfolio company sector.
- Represented InstaMed, a provider of cloud-based technology services in the health care payment and processing space, in connection with its sale to JPMorgan Chase & Co. (NYSE: JPM).
- Represented a UK-based professional services firm management team in the leveraged-recapitalization of 58 affiliated businesses located in 32 countries financed by a private equity fund, a major European bank, and a mezzanine debt provider.
- Advised in the competitive auction process resulting in the sale of one of the fastest growing energy suppliers in the U.S. to a NYSE-traded acquirer.
- Represented a manufacturer of life sciences measurement instrumentation in the acquisition of a division of a NYSE-traded instrument manufacturer.
- Represented a pharmaceutical company in its worldwide pre-clinical and clinical development activities.
- Represented a privately held clinical stage pharmaceutical company in its sale to a large pharmaceutical company.
- Advised in the acquisition of privately held contract research organization.
- Represented an e-commerce supply chain network for the chemical industry in connection with its merger.
- Advised financial services companies in connection with numerous stock and asset acquisitions.
- Served as outside counsel to multiple health care IT companies, and transaction examples include: (i) preferred equity financings; (ii) convertible note financings; (iii) acquisition and disposition transactions; and (iv) strategic licensing arrangements.
- Represented clients on both the buy- and sell-sides of acquisition transactions in which ESOPs were part of the shareholder base.
- Engaged as special counsel on a sell-side transaction to represent an ESOP in its capacity as the seller in an acquisition.
- Represented a manufacturer of diagnostic and detection testing in the food and beverage industry.
- Outside counsel to several fast-casual food and beverage restaurant in numerous equity and debt financing transactions and general governance matters.

AWARDS

- *Legal 500 United States*: M&A/Corporate and Commercial: Venture Capital and Emerging Companies (2025)
- Named to the Legal Elite list by Philadelphia SmartCEO (2011)

TOP AREAS OF FOCUS

- Corporate
- Corporate Governance
- Emerging Companies + Venture Capital
- Mergers + Acquisitions

ALL AREAS OF FOCUS

- Corporate
- Corporate Governance
- Emerging Companies + Venture Capital
- Food + Beverage
- Investment Funds + Investment Management Services
- Life Sciences Transactions
- Mergers + Acquisitions
- Private Equity
- Tax-Qualified Retirement Plans
- Technology

PROFESSIONAL/COMMUNITY INVOLVEMENT

- Steering Committee member, Emerging Companies Practice Group
- Adjunct professor at the University of Delaware's Horn Program for Entrepreneurship
- Frequent instructor and guest lecturer at Villanova University School of Law
- Member of the Board of Directors and Executive Committee of the British American Business Council of Greater Philadelphia

EDUCATION AND CERTIFICATIONS

EDUCATION

- Suffolk University Law School, J.D., *magna cum laude*, 2001, chief lead articles editor, *Transnational Law Review*
- King's College, B.S., *cum laude*, 1998, business administration

BAR ADMISSIONS

- Pennsylvania

SPEAKING ENGAGEMENTS

- Speaker, “Navigating a Challenging Landscape: Funding Sources, Strategies, and Best Practices for Businesses,” CBIZ Webinar, September 30, 2025.
- Speaker, “Side Letters in Venture Capital Financing: Drafting and Negotiating, Implications on Future Financing, Potential Traps,” Strafford Publications Webinar, April 8, 2025.
- Panelist, “Avoiding Deal Pitfalls,” ACC Greater Philadelphia Corporate & Securities Virtual CLE Webinar, August 22, 2023.
- Content Creator, “How to Create Your Comic Book Company – Legal and Business Considerations,” Comic-Con International 2023, July 21, 2023.
- Panelist, “Getting the Band Together: Club Deals & Co-Investment Fundraising Are On the Rise,” Troutman Pepper, June 23, 2022.

PUBLICATIONS

- Co-author, “What’s a Board to Do? Navigating a Down Round Financing,” *Troutman Pepper Locke*, October 13, 2025.
- Co-author, “What’s in a Down Round? Key Features of a Down Round,” *Troutman Pepper Locke*, October 6, 2025. Republished in *Insights: The Corporate & Securities Law Advisor*, December 2025.
- Co-author, “Unlocking Tax Planning Efficiency: The New Era of Online Section 83(b) Elections,” *Troutman Pepper Locke*, August 27, 2025.
- Podcast, “From Legislation to Implementation: Understanding Section 1202 Changes,” *Troutman Pepper Locke Podcast*, August 27, 2025.
- Co-author, “A Sharper Focus: Exploring VC Side Letters,” *Troutman Pepper Locke*, January 21, 2025.
- Co-author, “More Than a Majority: Chancery Court Provides Rare Guidance on Charter Amendments,” *Troutman Pepper*, February 16, 2023.